Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologySTU:8C5 -6.94%29 Days Inventory is 112.67 as of Jun. 2026, which is 43% below its 10-year median of 199.04. GuruFocus rates STU:8C5 with a GF Score™ of 29/100 and a GF Value™ of €0.83 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Coherus Oncology ranks better than 72.73% on this metric.
The historical rank and industry rank for Coherus Oncology's Days Inventory or its related term are showing as below:
STU:8C5'
s Days Inventory Range Over the Past 10 Years
Min: 93.31 Med: 199.04 Max: 1397.18
Current: 93.31
During the past 13 years, Coherus Oncology's highest Days Inventory was 1397.18. The lowest was 93.31. And the median was 199.04.
STU:8C5's Days Inventory is ranked better than 72.73% of 638
companies
in the Biotechnology industry
Industry Median: 179.22
vs STU:8C5: 93.31
Coherus Oncology's Days Inventory
increased
from Jun. 2025 (111.11) to Jun. 2026 (112.67).
It might indicate that Coherus Oncology's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Coherus Oncology's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.81.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coherus Oncology's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.37.
Coherus Oncology (STU:8C5) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Coherus Oncology's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coherus Oncology's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Coherus Oncology Days Inventory Related Terms
Coherus Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:8C5 vs NAUT, AVXL, SLNCF: Days Inventory Comparison
For the Biotechnology subindustry, Coherus Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (STU:8C5) has a Days Inventory of 112.67 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Coherus Oncology and its competitors. This is 43% below median its historical median of 199.04. Over the past decade, Coherus Oncology's Days Inventory has ranged from 93.31 to 1,397.18. According to the industry distribution chart, Coherus Oncology ranks #174 out of 638 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Coherus Oncology's Days Inventory too high?
Coherus Oncology's current Days Inventory of 112.67 is 43% below median its 10-year median of 199.04. Over the past 10 years, this metric has ranged from a low of 93.31 to a high of 1,397.18. The Biotechnology industry median Days Inventory is 179.22. Coherus Oncology's value of 112.67 is 37.1% below this industry median. Based on the distribution chart, Coherus Oncology ranks #174 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Days Inventory compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #174 out of 638 companies for Days Inventory. This puts Coherus Oncology in the upper half of its industry. The industry median Days Inventory is 179.22. Coherus Oncology's value of 112.67 is 37.1% below this benchmark. Historically, Coherus Oncology's own Days Inventory has ranged from 93.31 to 1,397.18 over the past decade. While the company's 10-year median is 199.04 vs. the industry median of 179.22, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 179.22, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Days Inventory of 112.67 is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Days Inventory is 179.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Days Inventory is 112.67, which is 43% below median its own 10-year median of 199.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (STU:8C5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.83, compared to a current price of €1.07 — trading 29.3% above its estimated fair value. The current Days Inventory is 112.67, which is 43% below median its 10-year median of 199.04 and 37.1% below the Biotechnology industry median of 179.22. Coherus Oncology's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Coherus Oncology (STU:8C5), the current Days Inventory is 112.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (STU:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.07 is trading 29.3% above its estimated GF Value™ of €0.83.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for STU:8C5:
Days Inventory: 112.67 (43% below median its 10-year median of 199.04)
GF Value™: €0.83 vs. price of €1.07 (29.3% above fair value)
Industry Position: 37.1% below the Biotechnology median (#174 of 638)
No single metric tells the full story. See the STU:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
29GF Score
Get the complete analysis for STU:8C5
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8C5 has been successfully added to your 
